Stem Cell Institute, University of MinnesotaMinneapolis, MN, USA; Lillehei Heart Institute, University of MinnesotaMinneapolis, MN, USA; Department of Integrative Biology and Physiology, University of MinnesotaMinneapolis, MN, USA.
Stem Cell Institute, University of MinnesotaMinneapolis, MN, USA; Lillehei Heart Institute, University of MinnesotaMinneapolis, MN, USA; Department of Integrative Biology and Physiology, University of MinnesotaMinneapolis, MN, USA; Department of Medicine/Cardiology, University of MinnesotaMinneapolis, MN, USA.
Front Cell Dev Biol. 2016 Sep 13;4:102. doi: 10.3389/fcell.2016.00102. eCollection 2016.
The heart has a limited ability to regenerate. It is important to identify therapeutic strategies that enhance cardiac regeneration in order to replace cardiomyocytes lost during the progression of heart failure. Cardiac progenitor cells are interesting targets for new regenerative therapies because they are self-renewing, multipotent cells located in the heart. Cardiac side population cells (cSPCs), the first cardiac progenitor cells identified in the adult heart, have the ability to differentiate into cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts. They become activated in response to cardiac injury and transplantation of cSPCs into the injured heart improves cardiac function. In this review, we will discuss the current literature on the progenitor cell properties and therapeutic potential of cSPCs. This body of work demonstrates the great promise cSPCs hold as targets for new regenerative strategies.
心脏的再生能力有限。因此，确定能够增强心脏再生的治疗策略非常重要，这有助于在心力衰竭进展过程中替换丢失的心肌细胞。心脏祖细胞是新再生疗法的一个有趣靶点，因为它们是位于心脏中的自我更新、多能细胞。心脏侧群细胞（cSPCs）是在成年心脏中首次鉴定的心脏祖细胞，它们具有分化为心肌细胞、内皮细胞、平滑肌细胞和成纤维细胞的能力。cSPCs 在心脏损伤时被激活，并且将 cSPC 移植到受损心脏中可以改善心脏功能。在这篇综述中，我们将讨论关于 cSPC 的祖细胞特性和治疗潜力的现有文献。这些研究工作表明，cSPC 作为新的再生策略靶点具有巨大的潜力。
